Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Zollinger-Ellison Syndrome × cixutumumab × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 Dermatologic 1 CNS 1

Conditions

Zollinger-Ellison Syndrome 1 Uveal Melanoma 1 Somatostatinoma 1 Paraganglioma 1 Insulinoma 1 Glucagonoma 1 Carcinoma, Merkel Cell 1 Carcinoma, Medullary 1

Interventions

veliparib 1 cixutumumab 1 Temozolomide 1 Salts 1 Octreotide 1 Everolimus 1 Capecitabine 1 Acetates 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed

CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡